Detalles de la búsqueda
1.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-33189178
2.
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Am J Hematol
; 96(6): 708-718, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755235
3.
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Am J Hematol
; 96(9): 1120-1130, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34062004
4.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Lancet Oncol
; 19(11): 1449-1458, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30348538
5.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
N Engl J Med
; 372(10): 944-53, 2015 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25738670
6.
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.
Haematologica
; 102(5): 895-902, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183846
7.
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Am J Hematol
; 97(3): E83-E86, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882831
8.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26655421
9.
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Nat Med
; 29(11): 2814-2824, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37857711
10.
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Haematologica
; 97(12): 1925-8, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22689676
11.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21507715
12.
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
J Hematol Oncol
; 14(1): 59, 2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33849608
13.
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica
; 100(5): e207-10, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25596270
14.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Lancet Haematol
; 7(3): e196-e208, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32014125
15.
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
Leuk Lymphoma
; 60(1): 172-179, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28583031
16.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Leukemia
; 37(10): 2129-2132, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634011
17.
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Leukemia
; 36(5): 1408-1411, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35210530
18.
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Leuk Lymphoma
; 56(10): 2826-33, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25797560
19.
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Hemasphere
; 4(6): e485, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33134869
Resultados
1 -
19
de 19
1
Próxima >
>>